TickerGuard
Buy Day today: Neutral (46) Mixed market breadth · no major macro event
EQ

Equillium Inc

Healthcare · Biotechnology

1.40$ -3.5% vs. previous close Closing price · As of: Oct 30, 2026

Ownership

Ownership Structure

Who owns Equillium Inc (EQ)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 58.3% of the shares are freely tradable; institutional investors hold 64.3%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 64.3%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 16.0%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 58.3%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 10.1%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 63Mio.

Largest Shareholders

Institutions

Institutions EQ
Name Stake (%) Shares Change (%) Date
HHG PLC 10.24 6,494,571 +10.8 03/31/2026
Jupiter Topco LLC 10.24 6,494,571 +0.0 06/30/2026
Decheng Capital LLC 7.01 4,447,308 +0.0 06/30/2026
Affinity Asset Advisors, LLC 6.47 4,100,000 +234.3 06/30/2026
ADAR1 Capital Management LLC 5.93 3,758,569 +0.9 06/30/2026
Aberdeen Group PLC 5.73 3,631,659 +8.3 06/30/2026
Woodline Partners LP 5.52 3,500,901 +0.0 06/30/2026
RA Capital Management, LLC 4.88 3,096,336 +0.0 06/30/2026
StemPoint Capital LP 3.18 2,016,607 +0.0 06/30/2026

Funds

Funds EQ
Name Stake (%) Shares Change (%) Date
abrdn Life Sciences Investors 7.03 4,458,351 +20.2 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?